Record Details

Effectiveness and safety of vancomycin powder injection locally applied in the prevention of prosthetic joint infection

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Effectiveness and safety of vancomycin powder injection locally applied in the prevention of prosthetic joint infection
 
Creator Wu, Xiaoshu
Gu, Qiangrong
 
Subject C-reactive protein
Interlukin
Neutrophil
Total hip arthroplasty
Total knee arthroplasty
 
Description 538-542
Prosthetic joint infection (PJI) is a rare but serious complication associated with considerable morbidity and financial burdens and other hardships for the individual. The available treatment options for PJI include both surgery and antimicrobial therapy. The surgical option includes debridement, antibiotics and implant retention (DAIR), that is usually recommended at initial stages, one stage or two stage revision arthroplasty at advanced stages. These treatments are expensive and time consuming and have around 11-30% failure rate. Therefore, there is an urgent need for an appropriate and affordable treatment strategy. Vancomycin serves as an active agent against the pathogens that have ability to cause potential damage to the wounds after surgery. In its powder form, it ensures adequate surgical site concentrations while minimizing the adverse effects caused by undetectable systemic distribution. Thus, we explored the effectiveness and safety of vancomycin powder injection locally applied in the prevention of prosthetic joint infection (PJI). A total of 90 inpatients who underwent total hip and knee arthroplasty from January 2018 to December 2019 were selected and randomly divided into control group (routine preventive antibiotic therapy) and treatment group (vancomycin applied based on the treatment of control group). The incidence of PJI and adverse reactions within 3 months after operation was observed. The changes in body temperature, neutrophil count, interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) levels were recorded before operation and 1, 3 and 7 days after treatment. Ninety days after treatment, the incidence rate of PJI in treatment group (0.00) was significantly lower than that of control group (8.89%) (P
 
Date 2022-07-11T06:48:35Z
2022-07-11T06:48:35Z
2022-07
 
Type Article
 
Identifier 0975-1009 (Online); 0019-5189 (Print)
http://nopr.niscpr.res.in/handle/123456789/60080
 
Language en
 
Publisher NIScPR-CSIR, India
 
Source IJEB Vol.60(07) [July 2022]